.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Dow
Mallinckrodt
Healthtrust
Harvard Business School
Teva
US Department of Justice
Julphar
Argus Health
AstraZeneca

Generated: December 12, 2017

DrugPatentWatch Database Preview

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION Drug Profile

« Back to Dashboard

Which patents cover Allegra-d 12 Hour Allergy And Congestion, and what generic alternatives are available?

Allegra-d 12 Hour Allergy And Congestion is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-four patent family members in thirty-one countries.

The generic ingredient in ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION is fexofenadine hydrochloride; pseudoephedrine hydrochloride. There are twenty-three drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride; pseudoephedrine hydrochloride profile page.

Summary for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

Drug patent expirations by year for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

Pharmacology for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRA-D 12 HOUR ALLERGY AND CONGESTIONfexofenadine hydrochloride; pseudoephedrine hydrochlorideTABLET, EXTENDED RELEASE;ORAL020786-002Jan 24, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,187,791 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
6,399,632 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

Country Document Number Estimated Expiration
New Zealand501248► Subscribe
Chile2004000304► Subscribe
Austria238773► Subscribe
Japan2002511102► Subscribe
Portugal998272► Subscribe
Estonia04294► Subscribe
Australia3973493► Subscribe
Israel133420► Subscribe
China1268050► Subscribe
Norway20000932► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Covington
Boehringer Ingelheim
Queensland Health
Fish and Richardson
Baxter
Teva
Express Scripts
McKesson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot